Myungmoon Pharm KRX:017180KOSPI
명문제약 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days2
Articles tracked1since Sep 11
In Q2 2026, Myungmoon Pharm reported revenue of ₩51.2bn, up 5.0% year on year, and an operating loss of ₩836m. Myungmoon Pharm (명문제약) appeared in 0 Korean news articles and 2 DART filings over the past seven days.
Filing signals Insider buying Swung to loss Screener
Myungmoon Pharm quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩51.2bn | +5.0% | −₩836m margin −1.6% | −₩1.7bn |
| Q1 2026 | ₩48.0bn | +4.6% | ₩294m margin 0.6% | −₩1.0bn |
| Q4 2025 derived | ₩50.8bn | +3.3% | ₩1.6bn margin 3.2% | ₩828m |
| Q3 2025 | ₩49.9bn | +6.1% | ₩454m margin 0.9% | −₩668m |
| Q2 2025 | ₩48.8bn | +5.8% | ₩5.7bn margin 11.6% | ₩3.4bn |
| Q1 2025 | ₩45.9bn | +3.7% | −₩912m margin −2.0% | −₩2.2bn |
| Q4 2024 derived | ₩49.1bn | +14.7% | ₩2.6bn margin 5.4% | ₩202m |
| Q3 2024 | ₩47.0bn | +8.7% | ₩902m margin 1.9% | −₩918m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Myungmoon Pharm top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.